-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Itolizumab in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Itolizumab in Systemic Lupus Erythematosus report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Itolizumab in Systemic Lupus Erythematosus Drug Details: Itolizumab (T1h, Alzumab...
-
Product Insights
NewNet Present Value Model: Sanofi’s Rilzabrutinib
Empower your strategies with our Net Present Value Model: Sanofi's Rilzabrutinib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Onureg in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Onureg in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Onureg in Diffuse Large B-Cell Lymphoma Drug Details: Azacitidine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Onureg in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Onureg in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Onureg in Relapsed Acute Myeloid Leukemia Drug Details: Azacitidine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anakinra in Intracerebral Hemorrhage
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anakinra in Intracerebral Hemorrhage report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anakinra in Intracerebral Hemorrhage Drug Details: Anakinra (Kineret) is an immunosuppressant...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anakinra in Community Acquired Pneumonia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anakinra in Community Acquired Pneumonia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anakinra in Community Acquired Pneumonia Drug Details: Anakinra (Kineret) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anakinra in Hospital Acquired Pneumonia (HAP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anakinra in Hospital Acquired Pneumonia (HAP) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anakinra in Hospital Acquired Pneumonia (HAP) Drug Details: Anakinra...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anakinra in Cytokine Release Syndrome (Cytokine Storm)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anakinra in Cytokine Release Syndrome (Cytokine Storm) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anakinra in Cytokine Release Syndrome (Cytokine Storm) Drug...
-
Sector Analysis
NewX-Ray Systems Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
X-Ray Systems Market Report Overview The X-ray Systems market size was $3.04 billion in 2023 and will grow at a CAGR of more than 2% during 2023-2033. The increasing prevalence of various chronic diseases, cardiac diseases, and neurological diseases has resulted in increased demand for medical imaging services. X-Ray Systems Market Outlook 2023-2033 ($ Billion) Buy the Full Report for More Insights on the X-ray systems Market Forecast Download a Free Sample Report The X-ray Systems market research report identifies...